Which has better earnings and valuation, SOLV or MDLN?

Solventum has higher earnings, but lower revenue than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.26B 1.80 $1.56B $8.16 10.50 Medline $28.43B 1.81 $1.16B $0.32 122.75

Is SOLV or MDLN more profitable?

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Medline N/A N/A N/A

Does the media favor SOLV or MDLN?

In the previous week, Solventum had 1 more articles in the media than Medline. MarketBeat recorded 11 mentions for Solventum and 10 mentions for Medline. Medline's average media sentiment score of 1.08 beat Solventum's score of 0.78 indicating that Medline is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medline 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GEHC or SOLV?

In the previous week, GE HealthCare Technologies had 48 more articles in the media than Solventum. MarketBeat recorded 59 mentions for GE HealthCare Technologies and 11 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 0.84 beat Solventum's score of 0.78 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 29 Very Positive mention(s) 6 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PHG or SOLV?

Solventum has a consensus target price of $86.00, suggesting a potential upside of 0.36%. Given Solventum's stronger consensus rating and higher possible upside, analysts clearly believe Solventum is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Solventum 1 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.46

Does the media favor PHG or SOLV?

In the previous week, Koninklijke Philips had 5 more articles in the media than Solventum. MarketBeat recorded 16 mentions for Koninklijke Philips and 11 mentions for Solventum. Solventum's average media sentiment score of 0.78 beat Koninklijke Philips' score of 0.55 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Solventum 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ZBH or SOLV?

Solventum has higher revenue and earnings than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.23B 2.21 $705.20M $3.85 24.47 Solventum $8.26B 1.80 $1.56B $8.16 10.50

Does the media refer more to ZBH or SOLV?

In the previous week, Zimmer Biomet had 6 more articles in the media than Solventum. MarketBeat recorded 17 mentions for Zimmer Biomet and 11 mentions for Solventum. Zimmer Biomet's average media sentiment score of 0.90 beat Solventum's score of 0.78 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, SOLV or SNN?

Solventum has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.26B 1.80 $1.56B $8.16 10.50 Smith & Nephew SNATS $6.16B 2.16 $625M N/A N/A

Does the media prefer SOLV or SNN?

In the previous week, Solventum had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 11 mentions for Solventum and 5 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 0.78 beat Smith & Nephew SNATS's score of 0.68 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Solventum (SOLV) Competitors

$85.69 +0.25 (+0.30%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$85.47 -0.22 (-0.26%)

As of 07/31/2026 07:56 PM Eastern

Compare

SOLV vs. MDLN, GEHC, PHG, ZBH, and SNN

Should you buy Solventum stock or one of its competitors? MarketBeat compares Solventum with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solventum include Medline (MDLN), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), and Smith & Nephew SNATS (SNN).

How does Solventum compare to Medline?

Solventum (NYSE:SOLV) and Medline (NASDAQ:MDLN) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

In the previous week, Solventum had 1 more articles in the media than Medline. MarketBeat recorded 11 mentions for Solventum and 10 mentions for Medline. Medline's average media sentiment score of 1.08 beat Solventum's score of 0.78 indicating that Medline is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medline	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has higher earnings, but lower revenue than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.26B	1.80	$1.56B	$8.16	10.50
Medline	$28.43B	1.81	$1.16B	$0.32	122.75

Solventum currently has a consensus target price of $86.00, indicating a potential upside of 0.36%. Medline has a consensus target price of $50.54, indicating a potential upside of 28.66%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Medline	N/A	N/A	N/A

Summary

Medline beats Solventum on 8 of the 14 factors compared between the two stocks.

How does Solventum compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

82.1% of GE HealthCare Technologies shares are held by institutional investors. 0.4% of GE HealthCare Technologies shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GE HealthCare Technologies currently has a consensus price target of $77.73, suggesting a potential upside of 14.27%. Solventum has a consensus price target of $86.00, suggesting a potential upside of 0.36%. Given GE HealthCare Technologies' higher probable upside, equities analysts clearly believe GE HealthCare Technologies is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

GE HealthCare Technologies has higher revenue and earnings than Solventum. Solventum is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.49	$2.08B	$4.36	15.60
Solventum	$8.26B	1.80	$1.56B	$8.16	10.50

In the previous week, GE HealthCare Technologies had 48 more articles in the media than Solventum. MarketBeat recorded 59 mentions for GE HealthCare Technologies and 11 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 0.84 beat Solventum's score of 0.78 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	29 Very Positive mention(s)	6 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a net margin of 17.33% compared to GE HealthCare Technologies' net margin of 9.33%. Solventum's return on equity of 23.51% beat GE HealthCare Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.33%	20.12%	5.74%
Solventum	17.33%	23.51%	7.63%

GE HealthCare Technologies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Solventum has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Summary

GE HealthCare Technologies beats Solventum on 10 of the 16 factors compared between the two stocks.

How does Solventum compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

13.7% of Koninklijke Philips shares are owned by institutional investors. 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Solventum has lower revenue, but higher earnings than Koninklijke Philips. Solventum is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.28	$1.01B	$1.36	19.33
Solventum	$8.26B	1.80	$1.56B	$8.16	10.50

Solventum has a net margin of 17.33% compared to Koninklijke Philips' net margin of 6.30%. Solventum's return on equity of 23.51% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	6.30%	14.38%	5.96%
Solventum	17.33%	23.51%	7.63%

Solventum has a consensus target price of $86.00, suggesting a potential upside of 0.36%. Given Solventum's stronger consensus rating and higher possible upside, analysts clearly believe Solventum is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Koninklijke Philips has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Solventum has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

In the previous week, Koninklijke Philips had 5 more articles in the media than Solventum. MarketBeat recorded 16 mentions for Koninklijke Philips and 11 mentions for Solventum. Solventum's average media sentiment score of 0.78 beat Koninklijke Philips' score of 0.55 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Solventum	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solventum beats Koninklijke Philips on 11 of the 16 factors compared between the two stocks.

How does Solventum compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Solventum has higher revenue and earnings than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.21	$705.20M	$3.85	24.47
Solventum	$8.26B	1.80	$1.56B	$8.16	10.50

In the previous week, Zimmer Biomet had 6 more articles in the media than Solventum. MarketBeat recorded 17 mentions for Zimmer Biomet and 11 mentions for Solventum. Zimmer Biomet's average media sentiment score of 0.90 beat Solventum's score of 0.78 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Zimmer Biomet shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zimmer Biomet has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Solventum has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Zimmer Biomet presently has a consensus price target of $102.00, suggesting a potential upside of 8.28%. Solventum has a consensus price target of $86.00, suggesting a potential upside of 0.36%. Given Zimmer Biomet's higher possible upside, equities analysts plainly believe Zimmer Biomet is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.24
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Solventum has a net margin of 17.33% compared to Zimmer Biomet's net margin of 9.05%. Solventum's return on equity of 23.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Solventum	17.33%	23.51%	7.63%

Summary

Zimmer Biomet beats Solventum on 9 of the 17 factors compared between the two stocks.

How does Solventum compare to Smith & Nephew SNATS?

Solventum (NYSE:SOLV) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Solventum has a net margin of 17.33% compared to Smith & Nephew SNATS's net margin of 0.00%. Solventum's return on equity of 23.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Smith & Nephew SNATS	N/A	N/A	N/A

Solventum has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.26B	1.80	$1.56B	$8.16	10.50
Smith & Nephew SNATS	$6.16B	2.16	$625M	N/A	N/A

Solventum presently has a consensus price target of $86.00, suggesting a potential upside of 0.36%. Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential downside of 1.92%. Given Solventum's stronger consensus rating and higher probable upside, analysts clearly believe Solventum is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Solventum had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 11 mentions for Solventum and 5 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 0.78 beat Smith & Nephew SNATS's score of 0.68 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Solventum beats Smith & Nephew SNATS on 11 of the 14 factors compared between the two stocks.

Get Solventum News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SOLV vs. The Competition

Export

Metric	Solventum	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$14.84B	$5.58B	$6.86B	$23.66B
Dividend Yield	N/A	1.79%	2.59%	4.21%
P/E Ratio	10.50	23.11	282.30	31.00
Price / Sales	1.80	56.88	564.98	81.82
Price / Cash	9.51	32.53	28.60	18.73
Price / Book	2.94	6.29	10.92	4.76
Net Income	$1.56B	$151.15M	$3.49B	$1.07B
7 Day Performance	6.47%	0.96%	-0.64%	-0.34%
1 Month Performance	9.56%	-3.50%	-5.24%	-0.53%
1 Year Performance	19.47%	2.31%	61.98%	19.19%

Solventum Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SOLV Solventum	2.9753 of 5 stars	$85.69 +0.3%	$86.00 +0.4%	+19.5%	$14.84B	$8.26B	10.50	20,000	Positive News Upcoming Earnings
MDLN Medline	4.6093 of 5 stars	$39.70 +2.5%	$50.54 +27.3%	N/A	$50.91B	$28.43B	124.06	45,000	Positive News Analyst Forecast
GEHC GE HealthCare Technologies	4.6968 of 5 stars	$61.12 +0.9%	$76.41 +25.0%	-2.6%	$27.56B	$20.63B	14.62	54,000	Trending News Earnings Report Analyst Forecast
PHG Koninklijke Philips	2.4993 of 5 stars	$25.06 -4.3%	N/A	-0.7%	$25.72B	$20.17B	21.47	65,340	Gap Up High Trading Volume
ZBH Zimmer Biomet	3.1926 of 5 stars	$92.15 +0.9%	$100.70 +9.3%	+3.9%	$17.67B	$8.23B	23.93	17,000	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SOLV) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solventum (SOLV) Competitors

SOLV vs. MDLN, GEHC, PHG, ZBH, and SNN

How does Solventum compare to Medline?

Summary

How does Solventum compare to GE HealthCare Technologies?

Summary

How does Solventum compare to Koninklijke Philips?

Summary

How does Solventum compare to Zimmer Biomet?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solventum (SOLV) Competitors

SOLV vs. MDLN, GEHC, PHG, ZBH, and SNN

How does Solventum compare to Medline?

Does the media favor SOLV or MDLN?

Which has better earnings and valuation, SOLV or MDLN?

Do analysts rate SOLV or MDLN?

Is SOLV or MDLN more profitable?

Summary

How does Solventum compare to GE HealthCare Technologies?

Do insiders & institutionals believe in GEHC or SOLV?

Do analysts rate GEHC or SOLV?

Which has stronger earnings and valuation, GEHC or SOLV?

Does the media refer more to GEHC or SOLV?

Is GEHC or SOLV more profitable?

Which has more volatility and risk, GEHC or SOLV?

Summary

How does Solventum compare to Koninklijke Philips?

Do insiders and institutionals hold more shares of PHG or SOLV?

Which has stronger valuation & earnings, PHG or SOLV?

Is PHG or SOLV more profitable?

Do analysts prefer PHG or SOLV?

Which has more volatility and risk, PHG or SOLV?

Does the media favor PHG or SOLV?

Summary

How does Solventum compare to Zimmer Biomet?

Which has better earnings and valuation, ZBH or SOLV?

Does the media refer more to ZBH or SOLV?

Do insiders & institutionals hold more shares of ZBH or SOLV?

Which has more risk & volatility, ZBH or SOLV?

Do analysts prefer ZBH or SOLV?

Is ZBH or SOLV more profitable?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Is SOLV or SNN more profitable?

Which has better earnings and valuation, SOLV or SNN?

Do analysts prefer SOLV or SNN?

Does the media prefer SOLV or SNN?

Which has more risk and volatility, SOLV or SNN?

Do insiders and institutionals hold more shares of SOLV or SNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools